KILITCHBSEKilitch Drugs India LtdMinimalNeutral
Announced Wed, 27 May · 11:34 IST

We are hereby submitting annual secretarial compliance report for the year ended 31st March, 2026

KILITCH · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-0.2%1-day move
₹180.30
prior close
₹182.87
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.3-0.4-0.4-0.3-0.2-0.2-1.8-3.5-0.6-7.4+2.0+2.6+0.9
Up moveDown movePending
AI summary

Kilitch Drugs has submitted its annual secretarial compliance report for FY2026, as mandated under SEBI Regulation 24A. The report, issued by practicing company secretary Deep Shukla & Associates, confirms the company largely complied with applicable SEBI regulations including LODR, ICDR, Takeover, Insider Trading, and Depositories regulations. Two minor fines were levied: Rs 11,800 each by BSE and NSE for delay in furnishing prior intimation about board meetings (both paid on August 26, 2025). The company also noted a technical glitch caused a missed SDD software entry for the June 2025 quarter regarding insider trading compliance. All other compliance parameters including secretarial standards, policy updation, website disclosures, related party transactions, and director disqualification checks showed compliant status.

Likely market impact

The filing indicates routine compliance with regulatory requirements. Minor fines for board meeting intimation delays have already been paid, suggesting no ongoing regulatory concerns. The technical glitch in insider trading software documentation appears isolated and explained.